Rivaroxaban significantly reduced thrombotic outcomes compared to LMWH after total knee arthroplasty, though it increased bleeding risks.
Does rivaroxaban reduce thrombotic outcomes compared to low molecular weight heparin for thrombo-prophylaxis in patients following total knee arthroplasty?
Rivaroxaban provides superior efficacy in preventing venous thromboembolism following total knee arthroplasty compared to LMWH, but at the cost of a significantly higher risk of bleeding complications.
Absolute Event Rate: 0% vs 0%
Our analysis showed that rivaroxaban when used as thrombo-prophylaxis following TKA, significantly reduced thrombotic outcomes when compared to LMWH. However, the risks of bleeding events including major and minor bleeding events were significantly increased in comparison to LMWH. Therefore, further larger studies should be able to confirm our hypothesis.
Dai et al. (Wed,) reported a other. Rivaroxaban significantly reduced thrombotic outcomes compared to LMWH after total knee arthroplasty, though it increased bleeding risks.